{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:24Z","timestamp":1792978404123,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Vienna","id":[{"id":"https:\/\/ror.org\/05n3x4p02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Germline\n                      <jats:italic>BRCA1<\/jats:italic>\n                      \/\n                      <jats:italic>2<\/jats:italic>\n                      pathogenic variants (g\n                      <jats:italic>BRCA<\/jats:italic>\n                      -PV) are associated with chemosensitivity in triple-negative breast cancer (TNBC), but whether higher pathologic complete response (pCR) rates translate into improved long-term outcomes remains uncertain. We assessed associations of g\n                      <jats:italic>BRCA<\/jats:italic>\n                      -PV status with pCR, recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in a real-world TNBC cohort treated with neoadjuvant chemotherapy (NACT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 293 patients with stage I-III TNBC diagnosed between 2007 and 2023 who were treated with NACT and underwent germline\n                      <jats:italic>BRCA1<\/jats:italic>\n                      \/\n                      <jats:italic>2<\/jats:italic>\n                      testing at a single tertiary center. Multivariable logistic and Cox regression models assessed pCR, RFS and BCSS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 293 patients, 56 (19.1%) carried g\n                      <jats:italic>BRCA<\/jats:italic>\n                      -PV. The overall pCR rate was 49.5% and was higher in carriers than noncarriers (73.2% vs. 43.9%, p&lt;0.001). After adjustment for age at diagnosis, clinical stage, NACT regimen, noncarriers had lower odds of pCR (OR 0.36, 95% CI 0.18\u20130.70, p=0.004). In Cox models, associations between g\n                      <jats:italic>BRCA<\/jats:italic>\n                      -PV status and RFS or BCSS did not reach statistical significance, either with or without adjustment for pCR, and estimates were imprecise. pCR was strongly associated with improved RFS (HR 0.24) and BCSS (HR 0.20) (both p&lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      g\n                      <jats:italic>BRCA-<\/jats:italic>\n                      PV carriers were more likely to achieve pCR after NACT, whereas associations with RFS or BCSS remained uncertain. The limited number of events and wide confidence intervals preclude firm conclusions regarding survival differences. Larger cohorts with longer follow-up are needed to clarify the relationship between g\n                      <jats:italic>BRCA<\/jats:italic>\n                      status, treatment response and long-term outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01914-8","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:46:08Z","timestamp":1789040768000},"page":"1340-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathologic complete response and survival according to germline BRCA1\/2 status in triple-negative breast cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"Paulina","family":"Gebhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heinzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Langs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Muhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1063-5352","authenticated-orcid":false,"given":"Yen Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"22","key":"1914_CR1","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathological features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer. 2012;118(22):5463.","journal-title":"Cancer"},{"issue":"2","key":"1914_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"A Garrido-Castro","year":"2019","unstructured":"Garrido-Castro A, Lin N, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176.","journal-title":"Cancer Discov"},{"issue":"1","key":"1914_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1914_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188678","volume":"1877","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Hu Y, Tang C, Guan X, Zhang W. Platinum-based systematic therapy in triple-negative breast cancer. Biochim Et Biophy Acta (Bba) Rev Cancer. 2022;1877(1):188678.","journal-title":"Biochim Et Biophy Acta (Bba) Rev Cancer"},{"key":"1914_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390464","volume":"43","author":"H Han","year":"2023","unstructured":"Han H, Vikas P, Costa R, Jahan N, Taye A, Stringer-Reasor E. Early-stage triple-negative breast cancer journey: beginning, end, and everything in between. Am Soc Clin Oncol Educ Book. 2023;43:E390464.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"13","key":"1914_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"L Korde","year":"2021","unstructured":"Korde L, Somerfield M, Carey L, Crews J, Denduluri N, Hwang E, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485\u2013505.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1914_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, Mcarthur HK, Mmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. New England J Med. 2020;382(9):810\u201321.","journal-title":"New England J Med"},{"key":"1914_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2018.10.014","volume":"72","author":"G Pelizzari","year":"2019","unstructured":"Pelizzari G, Gerratana L, Basile D, Fanotto V, Bartoletti M, Liguori A, et al. Post-neoadjuvant strategies in breast cancer: from risk assessment to treatment escalation. Cancer Treat Rev. 2019;72:7\u201314.","journal-title":"Cancer Treat Rev"},{"issue":"9938","key":"1914_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the Ctneobc pooled analysis. The Lancet. 2014;384(9938):164\u201372.","journal-title":"The Lancet"},{"issue":"3","key":"1914_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh B. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559\u201367.","journal-title":"Breast Cancer Res Treat"},{"key":"1914_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e43069","volume":"11","author":"M Antonini","year":"2025","unstructured":"Antonini M, Mattar A, Pereira T, Oliveira L, Teixeira M, Amorim A, et al. Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data. Heliyon. 2025;11:e43069.","journal-title":"Heliyon"},{"issue":"4","key":"1914_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"F Couch","year":"2015","unstructured":"Couch F, Hart S, Sharma P, Toland A, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304\u201311.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1914_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12885-018-4229-5","volume":"18","author":"YA Wang","year":"2018","unstructured":"Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HCS, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer. 2018;18(1):315.","journal-title":"BMC Cancer"},{"issue":"11","key":"1914_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"1914_CR15","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"K Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"7","key":"1914_CR16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, Pond\u00e8 N, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497\u2013508.","journal-title":"Ann Oncol"},{"issue":"1","key":"1914_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13053-022-00242-0","volume":"20","author":"O Caramelo","year":"2022","unstructured":"Caramelo O, Silva C, Caramelo F, Frutuoso C, Pinto L, Almeida-Santos T. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. Hered Cancer Clin Pract. 2022;20(1):20\u201334.","journal-title":"Hered Cancer Clin Pract"},{"issue":"25","key":"1914_CR18","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"A Tutt","year":"2021","unstructured":"Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2- mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"5","key":"1914_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.annonc.2022.03.008","volume":"33","author":"A Tutt","year":"2022","unstructured":"Tutt A, Garber J, Gelber R, Phillips K, Eisen A, Johannsson O, et al. VP1-2022: pre-specified event driven analysis of overall survival (OS) in the Olympia phase III trial of adjuvant olaparib (OL) in germline BRCA1\/2 mutation (gBRCAM) associated breast cancer. Ann Oncol. 2022;33(5):566\u20138.","journal-title":"Ann Oncol"},{"issue":"12","key":"1914_CR20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the olympia phase iii trial of adjuvant olaparib in patients with germline pathogenic variants in Brca1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368.","journal-title":"Ann Oncol"},{"issue":"10","key":"1914_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Lederer B, Hauke J, Loibl S, Kr\u00f6ber S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378\u201385.","journal-title":"JAMA Oncol"},{"issue":"19","key":"1914_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194571","volume":"14","author":"F Pavese","year":"2022","unstructured":"Pavese F, Capoluongo E, Muratore M, Minucci A, Santonocito C, Fuso P, et al. Brca mutation status in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: a pivotal role for treatment decision-making. Cancers (Basel). 2022;14(19):4571.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1914_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-024-07247-4","volume":"205","author":"R Mutai","year":"2024","unstructured":"Mutai R, Kuchuk I, Goldshtein A, Yerushalmi R, Rotem O, Maisel Lotan A, et al. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy. Breast Cancer Res Treat. 2024;205(2):241\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13058-025-02041-6","volume":"27","author":"H Kim","year":"2025","unstructured":"Kim H, Chun JW, Hwang J, Yun SG, Kim J, Jung SP, et al. Impact Of germline Brca1\/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study. Breast Cancer Res: Bcr. 2025;27:89.","journal-title":"Breast Cancer Res: Bcr"},{"issue":"22","key":"1914_CR25","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.2017.77.2285","volume":"36","author":"P Fasching","year":"2018","unstructured":"Fasching P, Loibl S, Hu C, Hart S, Shimelis H, Moore R, et al. Brca1\/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the Geparquinto study. J Clin Oncol. 2018;36(22):2281\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1914_CR26","first-page":"djw329","volume":"109","author":"MK Schmidt","year":"2017","unstructured":"Schmidt MK, Van Den Broek AJ, Raem T, Smit VTHBM, Westenend PJ, Brinkhuis M, et al. Breast cancer survival of Brca1\/Brca2 mutation carriers in a hospital-based cohort of young women. JNCI J Nat Cancer Ins. 2017;109(8):djw329.","journal-title":"JNCI J Nat Cancer Ins"},{"issue":"2","key":"1914_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"E Copson","year":"2018","unstructured":"Copson E, Maishman T, Tapper W, Cutress R, Greville-Heygate S, Altman D, et al. Germline Brca mutation and outcome in young-onset breast cancer (Posh): a prospective cohort study. Lancet Oncol. 2018;19(2):169\u201380.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1914_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"11","key":"1914_CR29","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2018","unstructured":"Kopanos C, Tsiolkas V, Kouris A, Chapple C, Albarca Aguilera M, Meyer R, et al. Varsome: the human genomic variant search engine. Bioinformatics. 2018;35(11):1978\u201380.","journal-title":"Bioinformatics"},{"issue":"28","key":"1914_CR30","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO.2011.35.2682","volume":"29","author":"B Arun","year":"2011","unstructured":"Arun B, Bayraktar S, Liu D, Gutierrez Barrera A, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29(28):3739\u201346.","journal-title":"J Clin Oncol"},{"key":"1914_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00674-y","volume":"10","author":"S Myers","year":"2024","unstructured":"Myers S, Sevilimedu V, Barrio A, Tadros A, Mamtani A, Robson M, et al. Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers. NPJ Breast Cancer. 2024;10:63.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1914_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10549-018-4797-8","volume":"171","author":"M Wunderle","year":"2018","unstructured":"Wunderle M, Gass P, H\u00e4berle L, Flesch V, Rauh C, Bani M, et al. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Res Treat. 2018;171(1):85\u201394.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1914_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019shaughnessy J, Untch M, Sikov W, Rugo H, Mckee M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (Brightness): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497\u2013509.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1914_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59151-0","volume":"16","author":"J Abraham","year":"2025","unstructured":"Abraham J, O\u2019connor L, Grybowicz L, Alba K, Dayimu A, Demiris N, et al. Neoadjuvant Parp inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: Partner, a randomized phase II\/III trial. Nat Commun. 2025;16(1):4269.","journal-title":"Nat Commun"},{"issue":"6","key":"1914_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-102 E4.","journal-title":"Cancer Cell"},{"issue":"2","key":"1914_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232\u201345.","journal-title":"Cancer Discov"},{"issue":"22","key":"1914_CR37","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med"},{"issue":"21","key":"1914_CR38","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, Mcarthur H, Pusztai L, Kummel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391(21):1981\u201391.","journal-title":"N Engl J Med"},{"key":"1914_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"R Leon-Ferre","year":"2023","unstructured":"Leon-Ferre R, Goetz M. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"issue":"1","key":"1914_CR40","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","volume":"15","author":"F Lynce","year":"2024","unstructured":"Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, et al. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the Oxel randomized phase ii study. Nat Commun. 2024;15(1):2691.","journal-title":"Nat Commun"},{"issue":"2","key":"1914_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/jamaoncol.2017.4298","volume":"4","author":"A Weiss","year":"2018","unstructured":"Weiss A, Chavez-Macgregor M, Lichtensztajn D, Yi M, Tadros A, Hortobagyi G, et al. Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol. 2018;4(2):203\u20139.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1914_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01393-z","volume":"23","author":"A Johansson","year":"2021","unstructured":"Johansson A, Trewin C, Fredriksson I, Reinertsen K, Russnes H, Ursin G. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Res. 2021;23(1):17.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"1914_CR43","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, Alhilli Z, et al. Nccn guidelines(R) insights: genetic\/familial high-risk assessment: breast, ovarian, And pancreatic. J Natl Compr Canc Netw. 2023;21(10):1000\u201310.","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"1914_CR44","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","volume":"38","author":"N Tung","year":"2020","unstructured":"Tung N, Boughey J, Pierce L, Robson M, Bedrosian I, Dietz J, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020;38(18):2080\u2013106.","journal-title":"J Clin Oncol"},{"issue":"723","key":"1914_CR45","doi-asserted-by":"publisher","first-page":"E702","DOI":"10.3399\/BJGP.2021.0655","volume":"72","author":"D Jones","year":"2022","unstructured":"Jones D, Di Martino E, Bradley S, Essang B, Hemphill S, Wright J, et al. Factors influencing symptom appraisal and help-seeking of older adults with possible cancer: a mixed-methods systematic review. Br J Gen Pract. 2022;72(723):E702\u201312.","journal-title":"Br J Gen Pract"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01914-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:03:36Z","timestamp":1792976616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01914-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01914-8","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Medical University of Vienna (EK Nr: 1153\/2023). Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}